Drug intelligence / Profile preview

Etoshine MR

Development stage: Unknown
Lead developer: Sun Pharmaceutical Industries
Modality: Small Molecules
Administration: Oral

Overview

**Etoshine MR** is an oral fixed-dose combination tablet marketed by Sun Pharma containing **etoricoxib 60 mg** and **thiocolchicoside 4 mg**. Etoricoxib is a selective cyclooxygenase-2 inhibitor NSAID that reduces prostaglandin-mediated pain and inflammation, while thiocolchicoside is a centrally acting muscle relaxant with activity at gamma-aminobutyric acid type A and glycine receptors. The product is used for short-term relief of painful musculoskeletal conditions involving inflammation and muscle spasm, including back pain and arthritic joint or muscle pain. ([1mg.com](https://www.1mg.com/drugs/etoshine-mr-tablet-64391))

Brand names: Etoshine MR
Other names: etoricoxib + thiocolchicoside

Targets

Glycine receptorGABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on Etoshine MR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Etoshine MR.

Explore the full profile